SLC5A2 and diabetes mellitus: Currently, drugs targeting AGEs-RAGE axis inhibition, such as pioglitazone or alagebrium (ALT-711), novel antihyperglycemic agents, namely glucagon-like peptide-1 receptor agonists (GLP-1RA; liraglutide, luraglutide, and semaglutide), and sodium-glucose cotransporter-2 inhibitors (SGLT2; empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) have been tested in studies involving both human and animals to reduce cardiovascular complications, including AS, in DM [96].